Scott D Patterson
Overview
Explore the profile of Scott D Patterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
4019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pulaski H, Harrison S, Mehta S, Sanyal A, Vitali M, Manigat L, et al.
Nat Med
. 2024 Nov;
31(1):315-322.
PMID: 39496972
Metabolic dysfunction-associated steatohepatitis (MASH) is a major cause of liver-related morbidity and mortality, yet treatment options are limited. Manual scoring of liver biopsies, currently the gold standard for clinical trial...
2.
Iyer J, Juyal D, Le Q, Shanis Z, Pokkalla H, Pouryahya M, et al.
Nat Med
. 2024 Aug;
30(10):2914-2923.
PMID: 39112795
Clinical trials in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis) require histologic scoring for assessment of inclusion criteria and endpoints. However, variability in interpretation has impacted clinical trial...
3.
Patterson S
Biotechniques
. 2023 Nov;
76(1):9-13.
PMID: 37994448
Scott Patterson (Gilead Sciences Inc., CA, USA) speaks to Ashling Cannon, Journal Development Editor at , about his career. Patterson is a biochemist and proteomics and biomarker/translational expert with over...
4.
Song K, Elboudwarej E, Zhao X, Zhuo L, Pan D, Liu J, et al.
PLoS One
. 2023 Oct;
18(10):e0293400.
PMID: 37883360
Clinical tumor tissues that are preserved as formalin-fixed paraffin-embedded (FFPE) samples result in extensive cross-linking, fragmentation, and chemical modification of RNA, posing significant challenges for RNA-seq-based gene expression profiling. This...
5.
Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D, et al.
J Clin Oncol
. 2023 Jun;
41(18):3278-3286.
PMID: 37315390
Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS,...
6.
Pan D, Odorizzi P, Schoenichen A, Abdelghany M, Chen S, Osinusi A, et al.
Commun Med (Lond)
. 2023 Jan;
3(1):2.
PMID: 36596885
Background: Remdesivir (RDV) is an intravenous antiviral with activity against SARS-CoV-2 for treatment of hospitalized COVID-19 patients with moderate-to-severe disease. Biomarkers associated with clinical outcomes have been identified for COVID-19,...
7.
Rasmussen D, Anstee Q, Torstenson R, Golding B, Patterson S, Brass C, et al.
J Hepatol
. 2022 Dec;
78(4):852-865.
PMID: 36526000
Biomarkers have the potential to accelerate drug development, as early indicators of improved clinical response, to improve patient safety, and for personalised medicine. However, few have been approved through the...
8.
Narayan S, Courcoubetis G, Mason J, Naghdloo A, Kolencik D, Patterson S, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230811
Metastatic colorectal cancer (mCRC) is characterized by its extensive disease heterogeneity, suggesting that individualized analysis could be vital to improving patient outcomes. As a minimally invasive approach, the liquid biopsy...
9.
Shah M, Cunningham D, Metges J, Van Cutsem E, Wainberg Z, Elboudwarej E, et al.
J Immunother Cancer
. 2021 Dec;
9(12).
PMID: 34893523
Background: Matrix metalloproteinase-9 (MMP9) selectively cleaves extracellular matrix proteins contributing to tumor growth and an immunosuppressive microenvironment. This study evaluated andecaliximab (ADX), an inhibitor of MMP9, in combination with nivolumab...
10.
Raghu G, Ley B, Brown K, Cottin V, Gibson K, Kaner R, et al.
Thorax
. 2019 Oct;
75(1):78-80.
PMID: 31611341
In this retrospective study of a randomised trial of simtuzumab in idiopathic pulmonary fibrosis (IPF), prodromal decline in forced vital capacity (FVC) was significantly associated with increased risk of mortality,...